Unknown

Dataset Information

0

Roflumilast, a Type 4 Phosphodiesterase Inhibitor, Shows Promising Adjunctive, Host-Directed Therapeutic Activity in a Mouse Model of Tuberculosis.


ABSTRACT: With phosphodiesterase inhibitors (PDE-Is) showing significant promise in shortening tuberculosis treatment, we assessed the effect of roflumilast, an FDA-approved type 4 PDE-I, in both acute and chronic murine models of tuberculosis. Alone, roflumilast had no effect on lung bacillary burden and mortality. However, when roflumilast was used in combination with isoniazid, a reduction in lung bacillary burden was observed. These data suggest that roflumilast may be a good candidate for tuberculosis host-directed therapy (HDT).

SUBMITTER: Maiga MC 

PROVIDER: S-EPMC4649180 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Roflumilast, a Type 4 Phosphodiesterase Inhibitor, Shows Promising Adjunctive, Host-Directed Therapeutic Activity in a Mouse Model of Tuberculosis.

Maiga Mariama C MC   Ahidjo Bintou Ahmadou BA   Maiga Mamoudou M   Bishai William R WR  

Antimicrobial agents and chemotherapy 20151005 12


With phosphodiesterase inhibitors (PDE-Is) showing significant promise in shortening tuberculosis treatment, we assessed the effect of roflumilast, an FDA-approved type 4 PDE-I, in both acute and chronic murine models of tuberculosis. Alone, roflumilast had no effect on lung bacillary burden and mortality. However, when roflumilast was used in combination with isoniazid, a reduction in lung bacillary burden was observed. These data suggest that roflumilast may be a good candidate for tuberculosi  ...[more]

Similar Datasets

2015-12-21 | GSE74687 | GEO
| S-EPMC7325721 | biostudies-literature
| S-EPMC2915539 | biostudies-literature
| S-EPMC4776074 | biostudies-literature
| S-EPMC7039813 | biostudies-literature
| S-EPMC9973281 | biostudies-literature
2022-11-29 | GSE178919 | GEO
| S-EPMC5418297 | biostudies-other
2018-08-02 | GSE99625 | GEO